ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk ESC Backs SGLT2i Plus GLP-1 in Diabetes with High CVD Risk
New ESC guidelines recommend using both an SGLT2 inhibitor and a GLP-1 receptor agonist simultaneously to treat people with type 2 diabetes and established cardiovascular disease.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors